This article is more than 6 months old
World Health Organisation includes Kaftrio on essential medicines list
WHO’s Model Lists of Essential Medicines was launched in 1977 to promote better access to medicines in developing countries, and is now used as a guide in decisions around supply and production of medicines.
Their expert committee meet every two years to review the list, looking at factors such as how common the disease or condition is, scientific evidence, and how effective the medicines are. The full list of medicines reflects the most vital public health needs.
International CF campaigning group, the Right to Breathe campaign, alongside a group of UK academics met with the WHO and submitted a 98-page application in October. This contained letters of support, signed by 35 national and international CF organisations, including Cystic Fibrosis Trust. They also visited WHO headquarters in Geneva, presenting lived experiences of life with and without Kaftrio.
Gayle Pledger of the Right to Breathe campaign said “Essential medicine status is not just symbolic - it’s a tool. It gives us leverage to challenge extortionate pricing, to unlock generic production, and to push governments into action. Today’s decision strengthens our global campaign for health equity and brings us closer to a future where every child with CF has the same chance to live.”
You can read more about Gayle’s work, and the campaign for global access here.
The addition of Kaftrio to the essential medicines list is an important step in the journey for better treatments for everyone with cystic fibrosis, around the world.
David Ramsden, Cystic Fibrosis Trust Chief Executive
Cystic fibrosis continues to make lives too tough and too short, which is why we will continue funding vital research to work towards a future where everyone can benefit from a life unlimited by CF.